ABBOTT LABORATORIES
For the period ended Dec 31, 2025. Filed Feb 20, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 20, 2026
ABT$109.93-3.2%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statement of Cash Flows
| Year Ended December 31 | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Cash Flow From (Used in) Operating Activities: | |||
| Net earnings | $6,524 | $13,402 | $5,723 |
| Adjustments to reconcile earnings to net cash from operating activities — | |||
| Depreciation | 1,434 | 1,340 | 1,277 |
| Amortization of intangible assets | 1,682 | 1,878 | 1,966 |
| Share-based compensation | 664 | 673 | 644 |
| Investing and financing losses, net | 65 | 482 | 126 |
| Trade receivables | (652) | (691) | (356) |
| Inventories | 195 | (58) | (232) |
| Prepaid expenses and other assets | (1,295) | (796) | (542) |
| Trade accounts payable and other liabilities | 954 | 356 | (760) |
| Income taxes | (5) | (8,028) | (585) |
| Net Cash From Operating Activities | 9,566 | 8,558 | 7,261 |
| Cash Flow From (Used in) Investing Activities: | |||
| Acquisitions of property and equipment | (2,171) | (2,207) | (2,202) |
| Acquisitions of businesses and technologies, net of cash acquired | (105) | — | (877) |
| Proceeds from business dispositions | — | 1 | 40 |
| Purchases of investment securities | (167) | (169) | (159) |
| Proceeds from sales of investment securities | 3 | 28 | 43 |
| Other | 18 | 9 | 22 |
| Net Cash From (Used in) Investing Activities | (2,422) | (2,338) | (3,133) |
| Cash Flow From (Used in) Financing Activities: | |||
| Proceeds from issuance of (repayments of) short-term debt, net and other | (115) | (100) | 21 |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 5 | 223 | 2 |
| Repayments of long-term debt and debt with maturities over 3 months | (1,504) | (660) | (2,498) |
| Purchases of common shares | (893) | (1,295) | (1,227) |
| Proceeds from stock options exercised | 396 | 264 | 167 |
| Dividends paid | (4,116) | (3,836) | (3,556) |
| Other | (82) | — | — |
| Net Cash From (Used in) Financing Activities | (6,309) | (5,404) | (7,091) |
| Effect of exchange rate changes on cash and cash equivalents | 71 | (96) | (23) |
| Net Increase (Decrease) in Cash and Cash Equivalents | 906 | 720 | (2,986) |
| Cash and Cash Equivalents, Beginning of Year | 7,616 | 6,896 | 9,882 |
| Cash and Cash Equivalents, End of Year | $8,522 | $7,616 | $6,896 |
| Supplemental Cash Flow Information: | |||
| Income taxes paid | $1,933 | $1,723 | $1,475 |
| Interest paid | 545 | 604 | 662 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.